Title: PROLYL HYDROXYLASE INHIBITORS

Abstract: The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I), which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
**INTERNATIONAL SEARCH REPORT**

**INTERNATIONAL SEARCH REPORT**

**A CLASSIFICATION OF SUBJECT MATTER**

**IPC**
C07D 471/02; (2006 01)

**USPC**
546/123

According to International Patent Classification (IPC) or to both national classification and IPC

**B FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

**U S**
546/123

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database searched during the international search (name of database and, where practicable, search terms used)

Please see Continuation Sheet

**C DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>HSIEH et al. Chronic intermittent administration of HIF prolyl hydroxylase inhibitor significantly induces erythropoietin and increases total hemoglobin in normal rhesus macaques Blood, 16 November 2005, Vol 106, No 11, Part 1, abstract pl69A, see entire abstract</td>
<td>I-18</td>
</tr>
</tbody>
</table>

**D**

Further documents are listed in the continuation of Box C

See patent family annex

<table>
<thead>
<tr>
<th>Special categories of cited documents</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;A&quot; document defining the general state of the art which is not considered to be of particular relevance</td>
<td></td>
</tr>
<tr>
<td>&quot;E&quot; earlier application or patent published on or after the international filing date</td>
<td></td>
</tr>
<tr>
<td>&quot;L&quot; document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td>
<td></td>
</tr>
<tr>
<td>&quot;O&quot; document referring to an oral disclosure, use, exhibition or other means</td>
<td></td>
</tr>
<tr>
<td>&quot;P&quot; document published prior to the international filing date but later than the priority date claimed</td>
<td></td>
</tr>
<tr>
<td>&quot;T&quot; later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td>
<td></td>
</tr>
<tr>
<td>&quot;X&quot; document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td>
<td></td>
</tr>
<tr>
<td>&quot;Y&quot; document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td>
<td></td>
</tr>
<tr>
<td>&quot;Z&quot; document member of the same patent family</td>
<td></td>
</tr>
</tbody>
</table>

Date of the actual completion of the international search
16 August 2008 (16 08 2008).

Date of mailing of the international search report
08 SEP 2008

**Authorized officer**
Patricia A Duffy

**Name and mailing address of the ISA/US**
Mail Stop PCT, Ann ISA/US Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No (571) 273-3201

Form PCTAS/2/10 (second sheet) (April 2007)
Continuation of B. FIELDS SEARCHED Item 3:
WEST, DIALOG
search stic struture search, HIF prolyl hydroxylase inhibitor(s), anemia, EPO, erythropoietm, pharmaceutical, heterocyclic, small molecule